Shingles Vaccine Recommendations

Introduction to Guideline Recommendations

The Advisory Committee on Immunization Practices (ACIP) recommends that zoster vaccination begins at age 60 years, despite the vaccine being FDA-licensed for use in persons aged 50 years and older 1, 2, 3
The American College of Physicians, as reflected in the Annals of Internal Medicine, supports ACIP's recommendation for zoster vaccination to start at age 60 years, not 50, for routine prevention in immunocompetent adults 1, 2, 3

The standard recommendation is a single dose of zoster vaccine for adults aged 60 years and older, regardless of prior herpes zoster history, as recommended by ACIP and supported by the American College of Physicians 1, 2, 3
While the FDA approved the vaccine for ages 50+, ACIP specifically chose age 60 as the threshold for routine vaccination, emphasizing the distinction between FDA licensure and ACIP recommendation 1, 2, 3
Healthcare personnel should receive the vaccine only if they are in the recommended age group (≥60 years), not based on occupation alone, according to ACIP guidelines 1, 3

Herpes zoster incidence increases substantially with age, with relatively lower risk in individuals under 60 compared to older adults, which informs ACIP's recommendation for vaccination starting at age 60 4
Resource allocation and cost-effectiveness considerations for population-level recommendations also play a role in setting the threshold at 60 years, as outlined by ACIP and the American College of Physicians 1, 2, 3

For immunocompromised patients, such as those with HIV, cancer, or autoimmune disease requiring immunosuppressive therapy, Shingrix (recombinant zoster vaccine) is recommended for adults aged ≥18 years, as per ACIP guidelines 4
The Centers for Disease Control and Prevention (CDC) also recommend Shingrix for immunocompromised individuals, highlighting the importance of vaccination in this population 4

For an immunocompetent 52-year-old male, inform the patient that routine vaccination is recommended starting at age 60 per ACIP guidelines, and explain that the vaccine is FDA-approved for his age but not part of standard recommendations 1, 2, 3
Consider individual discussion about off-guideline vaccination if he has specific risk factors or strong preference, taking into account ACIP's recommendations and the patient's unique circumstances 1, 2, 3

Do not confuse FDA approval age (50+) with ACIP recommendation age (60+) for routine vaccination in immunocompetent adults, as emphasized by ACIP and the American College of Physicians 1, 2, 3
Do not use live-attenuated Zostavax if the patient is or will become immunocompromised, and instead use Shingrix (recombinant vaccine), as recommended by ACIP and the CDC 4